Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Discover which Aristocrats ETF delivers the best value by fee and why cost matters for long-term returns. Learn quick tips to compare expense ratios and pick the right fund.
25,968 articlesEli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
The July Fourth week masked the broader strength in local housing markets. National data showed seasonal lull, but th...
PulteGroup accelerates its shift toward build-to-order homes to support margins as the 2026 housing market stays vola...
Three Dow components power the year’s rally with double-digit gains. Honeywell’s split plan and Chevron’s rising prod...
A fresh $75 million fund backs consumer brands with cultural punch. The 29-year investor went from early, risky bets ...
As Seer gears up for 2025 earnings, investors weigh growth, margins, and risk. This guide breaks down the drivers beh...
Regulatory tightening is reshaping crypto’s path. Barabash argues the most regulated platforms may become the biggest...
Antalpha's bold bet on tokenized gold XAUt has yielded more than $100 million in unrealized gains, with a recent tran...
Nebius inked a $27 billion AI infrastructure deal with Meta, locking in vast capacity and signaling its edge in the n...
Swarmer’s 520% debut gain transformed a modest-revenue drone-software company into a market curiosity. With no analys...
Chubb CEO Evan Greenberg releases a 25-page shareholder letter detailing strategic views on AI, China, and democracy’...
BuzzFeed shares surged after news that Byron Allen’s family office will take a majority stake. The move could reshape...